The estimated prevalence and incidence of late stage age related macular degeneration in the UK

British Journal of Ophthalmology

Volumn 96, Issue 5, 2012, Pages 752-756

  Owen, Christopher G ^a   Jarrar, Zakariya ^a   Wormald, Richard ^b,c   Cook, Derek G ^a   Fletcher, Astrid E ^b   Rudnicka, Alicja R ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COST; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH SERVICE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SEX DIFFERENCE; SOCIAL WORK; UNITED KINGDOM;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BAYES THEOREM; FEMALE; GEOGRAPHIC ATROPHY; GREAT BRITAIN; HUMANS; INCIDENCE; MACULAR DEGENERATION; MALE; MIDDLE AGED; PREVALENCE; SEX DISTRIBUTION; WET MACULAR DEGENERATION;

EID: 84860218671     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2011-301109     Document Type: Article

References (41)

1. Bunce C, Xing W, Wormald R. Causes of blind and partial sight certifications in England and Wales: April 2007-March 2008. Eye (Lond) 2010;24:1692-9.
2. Owen CG, Fletcher AE, Donoghue M, et al. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol 2003;87:312-17. (Pubitemid 36307906)
3. Minassian DC, Reidy A, Lightstone A, et al. Modelling the prevalence of age-related macular degeneration (2010-2020) in the UK: expected impact of anti-vascular endothelial growth factor (VEGF) therapy. Br J Ophthalmol 2011;95:1433-6.
4. Rudnicka AR, Jarrar Z, Wormald R, et al. Age and gender vairations in age realted macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology. Published Online First: 2011. doi:10.1016/j. ophtha.2011.08.038.
5. Wong TY, Liew G, Mitchell P. Clinical update: new treatments for age-related macular degeneration. Lancet 2007;370:204-6. (Pubitemid 47069522)
6. van Leeuwen R, Klaver CC, Vingerling JR, et al. Epidemiology of age-related maculopathy: a review. Eur J Epidemiol 2003;18:845-54. (Pubitemid 37169020)
7. Buch H, Nielsen NV, Vinding T, et al. 14-year incidence, progression, and visual morbidity of age-related maculopathydThe Copenhagen City Eye Study. Ophthalmology 2005;112:787-98. (Pubitemid 40631497)
8. Mitchell P, Wang JJ, Foran S, et al. Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study. Ophthalmology 2002;109:1092-7. (Pubitemid 34546916)
9. Klein R, Klein BE, Tomany SC, et al. Ten-year incidence and progression of age-related maculopathy. Ophthalmology 2002;109:1767-79.
10. Harding S. Photodynamic therapy in the treatment of subfoveal choroidal neovascularisation. Eye (Lond) 2001;15:407-12. (Pubitemid 32600866)
11. Meads C, Salas C, Roberts T, et al. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2003;7:v-98.
12. The Royal College of Ophthalmologists. Commissioning Contemporary AMD Services: A Guide for Commissioners and Clinicians. 2007. http://www.rcophth.ac. uk/ documents.asp?section=39§ionTitle=Publications (accessed Jan 2010).
13. Klein R, Klein BE, Knudtson MD, et al. Fifteen-year cumulative incidence of age-related macular degeneration. Ophthalmology 2007;114:253-62. (Pubitemid 46161820)
14. Wang JJ, Rochtchina E, Lee AJ, et al. Ten-year incidence and progression of age-related maculopathydThe Blue Mountains Eye Study. Ophthalmology 2007;114:92-8. (Pubitemid 46014292)
15. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995;39:367-74.
16. Klein R, Davis MD, Magli YL, et al. The Wisconsin age-related maculopathy grading system. Ophthalmology 1991;98:1128-34.
17. Office for National Statistics. Population Estimates for UK, England and Wales, Scotland and Northern Ireland, 2007. http://www.ons.gov.uk/ons/rel/pop- estimate/ population-estimates-for-ukeengland-and-walesescotland-and-northern- ireland/ 2007/index.html (accessed Sep 2011).
18. Office for National Statistics. Population Estimates for UK, England and Wales, Scotland and Northern Ireland, 2008. 2009. http://www.ons.gov.uk/ons/rel/ popestimate/ population-estimates-for-ukeengland-and-walesescotland-and- northernireland/ 2008/index.html (accessed Sep 2011).
19. Office for National Statistics. Population estimates for UK, England and Wales, Scotland and Northern Ireland, 2009. 2009. http://www.ons.gov.uk/ons/rel/ popestimate/ population-estimates-for-ukeengland-and-walesescotland-and- northernireland/ 2009/index.html (accessed Sep 2011).
20. Office for National Statistics. United Kingdom, Interim Life Tables, 1980-82 to 2007-09. 2010. http://www.ons.gov.uk/ons/publications/re-reference- tables.html? edition=tcm%3A77-61850 (accessed Sep 2011).
21. Office for National Statistics. UK Population Estimates and Projections 1971- 2083. 2010. http://www.ons.gov.uk/ons/taxonomy/index.html?nscl=Population +Estimates+by+Age+and+Sex (accessed Sep 2011).
22. Leske MC, Ederer F, Podgor M. Estimating incidence from age-specific prevalence in glaucoma. Am J Epidemiol 1981;113:606-13. (Pubitemid 11116909)
23. Augood CA, Vingerling JR, de Jong PT, et al. Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol 2006;124:529-35.
24. Das BN, Thompson JR, Patel R, et al. The prevalence of eye disease in Leicester - a comparison of adults of Asian and European descent. J R Soc Med 1994;87:219-22. (Pubitemid 24124039)
25. Gibson JM, Rosenthal AR, Lavery J. A study of the prevalence of eye disease in the elderly in an English community. Trans Ophthalmol Soc U K 1985;104:196-203. (Pubitemid 15137434)
26. Pauleikhoff D, Wormald RP, Wright L, et al. Macular disease in an elderly population. German J Ophthalmol 1992;1:12-15.
27. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72. (Pubitemid 38456293)
28. Colquitt JL, Jones J, Tan SC, et al. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2008;12:iiieiv, ix-201.
29. Klein R, Klein BEK, Jensen SC, et al. The 5-year incidence of age-related maculopathy in the Beaver Dam Eye Study. Invest Ophthalmol Vis Sci 1996;37:1916.
30. Klaver CC, Assink JJ, Van LR, et al. Incidence and progression rates of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci 2001;42:2237-41. (Pubitemid 32848852)
31. National Institute for Health and Clinical Excellence. Ranibizumab and Pegaptanip for the Treatment of Age-related Macular Degeneration: Response to Consultee and Commentator Comments on the draft scope. 2006. http://www.nice. org.uk/nicemedia/live/11700/34997/34997.pdf (accessed Jun 2011).
32. Van Leeuwen R, Klaver CC, Vingerling JR, et al. The risk and natural course of agerelated maculopathy: follow-up at 6 1/2 years in the Rotterdam study. [Erratum appears in Arch Ophthalmol. 2003 Jul;121(7):955]. Arch Ophthalmol 2003;121:519-26. (Pubitemid 36427639)
33. Karnon J, Czoski-Murray C, Smith K, et al. A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration. Health Technol Assess 2008;12:iiieiv, ix-124.
34. Cugati S, Cumming RG, Smith W, et al. Visual impairment, age-related macular degeneration, cataract, and long-term mortality: the Blue Mountains Eye Study. Arch Ophthalmol 2007;125:917-24. (Pubitemid 47076429)
35. Thiagarajan M, Evans JR, Smeeth L, et al. Cause-specific visual impairment and mortality: results from a population-based study of older people in the United Kingdom. Arch Ophthalmol 2005;123:1397-403. (Pubitemid 41429740)
36. Xu L, Wang YX, Wang J, et al. Mortality and ocular diseases: the Beijing Eye Study. Ophthalmology 2009;116:732-8.
37. Chakravarthy U, Wong TY, Fletcher A, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol 2010;10:31.
38. Thornton J, Edwards R, Mitchell P, et al. Smoking and age-related macular degeneration: a review of association. Eye (Lond) 2005;19:935-44. (Pubitemid 43114972)
39. Hicks J, Allen G. A Century of change: Trends in UK Statistics since 1900. Res paper RP99/111. 1999 http://www.parliament.uk/briefing-papers/RP99-111 (accessed Jun 2011).
40. Office for National Statistics. Current EstimatesdPopulation Estimates by Ethnic group Mid-2009. 2011. http://www.statistics.gov.uk/statbase/product.asp? vlnk=14238 (accessed Jun 2011).
41. Kawasaki R, Yasuda M, Song SJ, et al. The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology 2010;117:921-7.